Clinical Trial Update: Clinical and Dosimetric Study of Patients Treated With 177Lu-PSMA-617 for Prostate Cancer.

View source ↗

Summary

An ongoing study evaluating clinical outcomes and dosimetry in patients with prostate cancer treated with 177Lu-PSMA-617, including metastatic cases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 177Lu-PSMA-617 (Lutetium-177 PSMA-617)

Snippet

Sponsor: Institut Bergonié | Conditions: Prostate Cancer, Metastasis | Status: RECRUITING